



AOXIN Q & M DENTAL GROUP LIMITED
(Company Registration Number: 201110784M)
(Incorporated in the Republic of Singapore)

PRESS RELEASE BY ASSOCIATED COMPANY, ACUMEN DIAGNOSTICS PTE. LTD.

1. The Board of Directors (the “**Board**” or the “**Directors**”) of Aoxin Q & M Dental Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) wishes to update the shareholders of the Company that the Group’s 49% owned associated company, Acumen Diagnostics Pte. Ltd., has made a press release in relation to its PCR capabilities to tackle Omicron COVID-19 variant on 3 December 2021.
2. Please see attached press release for more information.

By Order of the Board

Dr. Shao Yongxin
Executive Director and Group Chief Executive Officer

3 December 2021

For more information, please contact:

Deputy CEO

Ryan San Yi Leong @ Tan Yi Leong
Tel: 6235 1188
Email: ryan@aoxin.sg

This announcement has been reviewed by the Company’s Sponsor, SAC Capital Private Limited (the “Sponsor”). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (“Exchange”) and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: (65) 6232 3210) at 1 Robinson Road, #21-00, AIA Tower, Singapore 048542.

Acumen Diagnostics' PCR capabilities to tackle Omicron COVID-19 variant

- *Highly accurate, cost-effective, affordable PCR tests with 2 laboratories able to undertake 7000 tests daily*
- *PCR test kits able to detect COVID-19 positive cases including those infected with Omicron variant*
- *Homegrown medical technology company that is fully integrated to manufacture PCR test kits locally*
- *One of the few companies in Singapore with proprietary technology in testing*



Acumen Diagnostics' series of Acu-Corona and SatuGen COVID-19 PCR test kits can detect the presence of the Omicron variant in SARS-CoV-2 samples

Singapore, 3 December 2021 – Homegrown medical technology Company, **Acumen Diagnostics Pte. Ltd.** (“Acumen Diagnostics” or the “Company”), a 51% owned subsidiary of Q & M Dental Group (Singapore) and 49% owned by Aoxin Q & M Dental, today announced that its proprietary, locally-manufactured polymerase chain reaction (“PCR”) test kits Acu-Corona 2.0 and Acu-Corona Duplex are able to detect COVID-19 positive cases infected with the Omicron variant.

Dr Ong Siew Hwa, (王秀华博士) Executive Director of Aoxin Q & M Dental and Chief Executive Officer & Chief Scientist of Acumen Diagnostics said, *“As the COVID-19 threat continues to evolve with the emergence of a potentially more transmissible variant, Omicron, highly-accurate and cost-effective COVID-19 testing becomes even more important to detect and help curb the spread of the virus.*

With PCR tests remaining the gold standard to detect COVID-19, Acumen Diagnostics remains well-positioned to help Singapore tackle this new challenge posed by the virus, with our effective and affordable PCR test kits that are equipped to detect COVID-19 positive cases infected with Delta and Omicron, as well as our laboratory testing capabilities that can run 7000

tests daily. We will continue to contribute to national COVID-19 testing efforts to support Singapore's safe and sustainable re-opening."

In addition to detecting COVID-19 positive cases infected with the Delta variant, the Company's proprietary PCR test kits are able to detect COVID-19 positive cases infected with the Omicron variant as well.

The Acu-Corona 2.0 PCR test targets two COVID-19 genes - RdRp and E, while the Acu-Corona Duplex PCR test targets the E gene and S gene. The portion of the S gene targeted by the Acu-Corona Duplex PCR test does not contain any of the 32 mutations that occurred in the Omicron variant, hence it can detect the Omicron variant without any loss of sensitivity.

This proprietary technology used in PCR test kits and laboratory testing is developed and owned by Acumen Diagnostics. Being locally manufactured, the Company's test kits can be deployed quickly and are more cost-effective and allow for greater self-sufficiency, compared to that of its peers imported from overseas.

Acumen Diagnostics possesses deep technical capabilities and the supporting infrastructure in molecular diagnostics, spanning R&D, manufacturing, and clinical laboratory testing, with 2 laboratories that are able to process 7000 COVID-19 diagnostics tests daily.

- End -

About Acumen Diagnostics Pte. Ltd.

Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics") is a homegrown Singaporean, award-winning medical technology company. It is fully integrated with functions in research and development, manufacturing, as well as commercialisation of molecular diagnostics by distribution as well as conducting clinical laboratory testing services for (including but not limited to) infectious diseases, cancer, and COVID-19. It has also actively established frontline services such as COVID-19 on-site swabbing operations.

Acumen Diagnostics is a 51% subsidiary of SGX-listed Q & M Dental Group (Singapore) Limited (SGX: 1D4.SI) and 49%-owned by SGX-listed Aoxin Q & M Dental Group Limited (SGX: QC7.SI).

For more information, please visit the company website at www.acumen-research.com.

For more information, please contact:

Waterbrooks Consultants Pte. Ltd.

+65 6958 8008, query@waterbrooks.com.sg

**PRESS RELEASE
FOR IMMEDIATE RELEASE**



Wayne Koo (M): +65 9338 8166, wayne.koo@waterbrooks.com.sg

Derek Yeo (M): +65 9791 4707, derek@waterbrooks.com.sg